About this Research Topic
Cancer remains a significant and debilitating disease, posing a formidable challenge to human health, and its incidence continues to rise steadily. The urgency to address this pressing issue has fueled extensive research efforts aimed at understanding the complexities of cancer biology, improving diagnostic methods, and developing effective therapeutic strategies. In this context, the integration of advanced nanotechnology has emerged as a compelling avenue for combating cancer. Nanoparticles, with their unique physicochemical properties, serve as versatile platforms for multifunctional applications in cancer theranostics. These nanoparticles can be engineered to carry therapeutic payloads, such as chemotherapeutic drugs or photosensitizers, while simultaneously incorporating imaging contrast agents for precise tumor localization. This synergistic combination allows for enhanced treatment efficacy and reduced off-target effects.
In the realm of cancer imaging, the integration of nanotechnology has revolutionized the field by enabling high-resolution and real-time visualization of tumor characteristics. With their tunable properties and versatile surface modifications, nanoparticles can serve as valuable platforms for targeted imaging contrast agents. By conjugating these nanoparticles with specific ligands or antibodies, they can be directed towards cancer cells or their associated biomarkers, facilitating precise imaging of tumor sites and providing valuable insights into disease progression. Moreover, the therapeutic potential of nanotechnology in cancer treatment is profound. Nanoparticles can be engineered to overcome many limitations encountered with traditional therapies, such as poor solubility, limited bioavailability, and systemic toxicity. By encapsulating therapeutic agents within nanoparticles, drug delivery can be enhanced, leading to improved efficacy and reduced off-target effects. Meanwhile, the ability to remotely control drug release from nanocarriers offers precise spatiotemporal control over therapy, optimizing treatment outcomes. Furthermore, different imaging and treatment modalities can be integrated into one single nanoplatform, resulting in synergistic effects.
The convergence of advanced nanotechnology with cancer imaging and treatment capabilities presents a transformative paradigm in the field of oncology. This Research Topic aims to offer timely updates in the state-of-the-art theragnostic nanoplatforms for cancer diagnosis and treatment. Original research papers, reviews, and mini-review papers are all welcome. The scope of the Research Topic includes:
1. Smart drug delivery systems such as pH-, temperature-, photo-, redox-, and enzyme-responsive materials.
2. Innovative nanomaterials for cancer diagnosis such as magnetic resonance imaging, fluorescence imaging, photoacoustic imaging, and Raman imaging contrast agents.
3. Advanced cancer therapeutic modalities such as photothermal therapy, photodynamic therapy, sonodynamic therapy, immunotherapy, and catalytic therapy.
4. Multifunctional theragnostic nanoplatforms that combine both imaging and treatment units with synergistic effects.
5. Synthetic methods for the preparation of novel nanomaterials for biomedical applications.
In the realm of cancer imaging, the integration of nanotechnology has revolutionized the field by enabling high-resolution and real-time visualization of tumor characteristics. With their tunable properties and versatile surface modifications, nanoparticles can serve as valuable platforms for targeted imaging contrast agents. By conjugating these nanoparticles with specific ligands or antibodies, they can be directed towards cancer cells or their associated biomarkers, facilitating precise imaging of tumor sites and providing valuable insights into disease progression. Moreover, the therapeutic potential of nanotechnology in cancer treatment is profound. Nanoparticles can be engineered to overcome many limitations encountered with traditional therapies, such as poor solubility, limited bioavailability, and systemic toxicity. By encapsulating therapeutic agents within nanoparticles, drug delivery can be enhanced, leading to improved efficacy and reduced off-target effects. Meanwhile, the ability to remotely control drug release from nanocarriers offers precise spatiotemporal control over therapy, optimizing treatment outcomes. Furthermore, different imaging and treatment modalities can be integrated into one single nanoplatform, resulting in synergistic effects.
The convergence of advanced nanotechnology with cancer imaging and treatment capabilities presents a transformative paradigm in the field of oncology. This Research Topic aims to offer timely updates in the state-of-the-art theragnostic nanoplatforms for cancer diagnosis and treatment. Original research papers, reviews, and mini-review papers are all welcome. The scope of the Research Topic includes:
1. Smart drug delivery systems such as pH-, temperature-, photo-, redox-, and enzyme-responsive materials.
2. Innovative nanomaterials for cancer diagnosis such as magnetic resonance imaging, fluorescence imaging, photoacoustic imaging, and Raman imaging contrast agents.
3. Advanced cancer therapeutic modalities such as photothermal therapy, photodynamic therapy, sonodynamic therapy, immunotherapy, and catalytic therapy.
4. Multifunctional theragnostic nanoplatforms that combine both imaging and treatment units with synergistic effects.
5. Synthetic methods for the preparation of novel nanomaterials for biomedical applications.
Keywords: drug delivery, magnetic resonance imaging, fluorescence imaging, photoacoustic imaging, Raman imaging, photothermal therapy, photodynamic therapy, sonodynamic therapy, immunotherapy, catalytic therapy, cancer theragnostic
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
